What question did this study set out to answer?

To assess the feasibility of using a point-of-care isoenzyme type M2 pyruvate kinase stool test to triage symptomatic patients requiring esophagogastroduodenoscopy for suspected gastric cancer.

July 1, 2026JCO oncology advances.Open Access

Feasibility of Using Point-of-Care Isoenzyme Type M2 Pyruvate Kinase Quick Stool Test to Facilitate Earlier Diagnosis of Gastric Cancer in Rwanda

View Full Paper

Ask AI

Bookmark

Authors

MCMary D. Chamberlin STSharon Thomson IRIvy Riaño

Discussion

Member takes

Overview

Feasibility study reveals operational challenges of point-of-care M2 pyruvate kinase stool testing in symptomatic patients, highlighting triage potential alongside significant resource barriers.

Key Points

To assess the feasibility of using a point-of-care isoenzyme type M2 pyruvate kinase stool test to triage symptomatic patients requiring esophagogastroduodenoscopy for suspected gastric cancer.
Enrolled patients presenting with gastrointestinal symptoms scheduled for endoscopy during the Annual Rwanda Endoscopy Week from 2022 to 2024.
Collected patient stool samples for point-of-care M2 pyruvate kinase testing alongside baseline demographics, endoscopy findings, and gastric biopsy specimens.
Study recruitment was discontinued after consenting 82 patients due to a Marburg virus epidemic, with 46 having incomplete data and 3 failing eligibility criteria.
Both point-of-care M2 pyruvate kinase and esophagogastroduodenoscopy evaluations were completed in 36 of 82 patients (43.9%), while definitive pathology results were obtained in 19 of 82 patients (23%).

Cite This Study

Chamberlin et al. (2026) studied this question.

synapsesocial.com/papers/6a94d54548a688da70e60d7c https://doi.org/10.1200/oa-25-00200

View Full Paper

Ask AI

Bookmark

July 1, 2026JCO oncology advances.Open Access

Feasibility of Using Point-of-Care Isoenzyme Type M2 Pyruvate Kinase Quick Stool Test to Facilitate Earlier Diagnosis of Gastric Cancer in Rwanda

View Full Paper

Ask AI

Bookmark

Authors

MCMary D. Chamberlin STSharon Thomson IRIvy Riaño

Discussion

Member takes

Overview

Feasibility study reveals operational challenges of point-of-care M2 pyruvate kinase stool testing in symptomatic patients, highlighting triage potential alongside significant resource barriers.

Key Points

To assess the feasibility of using a point-of-care isoenzyme type M2 pyruvate kinase stool test to triage symptomatic patients requiring esophagogastroduodenoscopy for suspected gastric cancer.
Enrolled patients presenting with gastrointestinal symptoms scheduled for endoscopy during the Annual Rwanda Endoscopy Week from 2022 to 2024.
Collected patient stool samples for point-of-care M2 pyruvate kinase testing alongside baseline demographics, endoscopy findings, and gastric biopsy specimens.
Study recruitment was discontinued after consenting 82 patients due to a Marburg virus epidemic, with 46 having incomplete data and 3 failing eligibility criteria.
Both point-of-care M2 pyruvate kinase and esophagogastroduodenoscopy evaluations were completed in 36 of 82 patients (43.9%), while definitive pathology results were obtained in 19 of 82 patients (23%).

Cite This Study

Chamberlin et al. (2026) studied this question.

synapsesocial.com/papers/6a94d54548a688da70e60d7c https://doi.org/10.1200/oa-25-00200

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark